STORM in the News

Scrip Intelligence: STORM’s METTL3 Inhibitor Effective Against AML

Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML

To read the full article, please click here

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 2022 Dates To be Confirmed